Status:
RECRUITING
The Beneficial Effect of TJ-134 for Patients With Symptomatic Pneumatosis Cystoides Intestinalis
Lead Sponsor:
Showa Inan General Hospital
Conditions:
Pneumatosis Cystoides Intestinalis
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to is administered to patients with symptomatic pneumatosis cystoides intestinalis (PCI) as compared with lactomin for 8 weeks.
Detailed Description
1. Based on endoscopic finding, patients with symptomatic PCI are recruited. 2. After enrollment, abdominal symptoms are evaluated and abdominal CT is performed. 3. Patients were randomized in a 1:1 r...
Eligibility Criteria
Inclusion
- typical findings of PCI on colonoscopy; Line or pebble like sessile cysts are distributed around the colon with normal overlying mucosa
Exclusion
- patients can not take Keishi-ka-shakuyaku-daio-to（TJ-134）
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04368663
Start Date
May 1 2020
End Date
December 31 2026
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Showa Inan General hospital
Komagane, Nagano, Japan, 399-4117